SOURCE: Yes International, Inc.

January 20, 2016 10:00 ET

AdvantaMeds Solutions USA Fund 1, Inc.'s Convertible Preferred Stock Shares Approved for Sale, First Time Regulators Allow Convertible Preferred Stock Shares Application for a Cannabis Company

CHICAGO, IL--(Marketwired - January 20, 2016) - AdvantaMeds Solutions USA Fund 1, Inc. ("AdvantaMeds"), a cannabis Corporation, announces that the US SEC approved its Convertible Preferred Stock Shares for sale. The Company appears to be the first ever Convertible Preferred Stock Shares approved for a cannabis operation.

With US SEC approval, the Company, its legal team and Corporate advisors remain focused on funding the Convertible Preferred Stock Shares through a number of underwriters.

Convertible Preferred Stock Shares proceeds enable AdvantaMeds to grow operations with the construction of potentially the largest fully licensed and approved commercial cannabis facility in North America. AdvantaMeds has entered into a purchase agreement with a company in Colorado that owns a 104,000 sq. ft. industrial building. Investment proceeds will be used for improvements to increase the size to a 223,270 sq. ft. facility.

The increasing demand for cannabis as a medicine for a number of ailments continues to be a proven alternative to pharmaceutical regimens. Positioning the Corporation to take maximum advantage of this demand with high-quality products remains a major operational objective.

Management believes that it can obtain increasing revenues, garner greater market share and look for and close upon quality acquisitions to increase its presence as a commercial cannabis operator.

Geoff Thompson, President, AdvantaMeds Solutions USA Fund 1, Inc., states, "After months of hard work we finally received AdvantaMeds' US SEC Convertible Preferred Stock Shares approval. As an historical event, not just for Advantameds, but for the whole cannabis industry, regulators allowed a Convertible Preferred Stock Shares issuance for an industry that in the past wasn't taken seriously." 

He further states, "Convertible Preferred Stock Shares holders who purchase a stake in Advantameds, become the first in this historic event for both the Corporation and the cannabis industry."

Adavantameds Solutions USA Fund 1, Inc. continues with commitments in earnest to provide a high-quality, legally regulated cannabis product which can provide medical relief to the inflicted, but also provide a positive balance sheet and bottom-line earnings for its investors.

For further information about the Convertible Preferred Stock Shares and the Corporation, Contact Mr. Richard Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com.

Forward-looking Statements:
This news release contains certain statements that may constitute forward-looking information within the meaning of applicable securities laws. This information includes, but is not limited to: (i) The Company's ability to fully raise $20,000,000; and (ii) legal rules in the medical marijuana industry remaining consistent at the time of this release. Although AdvantaMeds Solutions USA Fund 1, Inc. believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because management can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks

Contact Information